Since 2010, Oncotarget has been a well-known platform for the submission and publication of research papers and articles about oncology and related subjects. The research papers and articles are published weekly so that anything new of importance can be observed by the medical community at large as quickly as possible.
Oncotarget was founded in 2010, and the Editors-in-Chief are Mikhail Blagosklonny and Andrei V. Gudkov, both of the Roswell Park Cancer Institute, Buffalo, NY. Well-researched studies of the latest discoveries and procedures in the oncology field have a long history of saving lives when seemingly all hope has been lost.
Some of the fields in addition to oncology that are considered appropriate for submission, due to their relevance to the study of oncology include Endocrinology, Geotarget/Aging, Cardiology, Pharmacology, Metabolism, Neuropathologic/Neuroscience, Immunology/Microbiology and Cell and Mol Biology.
Researchers and authors submit their papers and manuscripts to the Editorial Board of Oncotarget. The editors on YouTube then thoroughly read and evaluate the paper, taking into consideration the merit of the paper, its uniqueness, its accuracy, the citations used as proofs, and the overall methods used to prove the main thesis.
Care is taken to research whether or not similar subjects have been written about and whether this paper is different enough in scope and proofs to warrant a new look. The complexity of oncology on scimagojr.com, particularly at the cellular level, leaves lots of room for expansion, yet there must be enough of a divergence to warrant a new look.
Editors work in pairs, and they must be expert in the subject in which each author submits. This peer review technique maintains the proper balance in expertise and accurate presentations, as the reviewers are well-versed on the subject matter.
Care is taken to that there is no other theme or distraction to cloud the intent and direction of the submitted item. For example, slander, opinion, political inferences, sexual orientation, racial or gender inferences, or any other distractive dialogue will not be permitted.
None of the material may be used by the editorial board for any personal use and all of the material contained in the submitted copy will be held as confidential, except with the author. This keeps the content pure and when published the medical community can be assured that the content is pristine and untainted.
Learn more about Oncotarget: